We all believe that our market cap ought to be higher here, likewise as an IMGN investor since it first came public, roughly twice as long as NWBO, it's market cap is only slightly higher than NWBO today. I strongly believe in the potential of both, but both are in similar situations, their technologies must be validated.
IMGN is perhaps a few months ahead, having submitted a BLA, but we really don't know if NWBO has, or when they're about to do so. In some ways I believe investors may have more doubts about IMGN's drug, but I believe both to be very approvable.
I believe the potential of DCVax-L is greater, so in the long run I believe we'll have the greater market cap, and that's why my investment is much more concentrated here, but both companies should have multiples of their current prices by the end of this year whether approvals are obtained by then, or delayed to early next year.
As doubt is removed on the likelihood of approval I believe our market cap can easily go to a few billion, if we gain major media coverage prior to approval, or a partnership, it could go substantially higher than that, perhaps even into double digit billions. Double digit billions will certainly come post approvals.
I believe that whether we get the Journal before ASCO or now, what will be said in the Experts Theater should remove much of the doubt. Certainly it would be better if they have the Journal to quote, but with or without it they ought to be coming out of the quiet period there, and I believe investors will be impressed by what they've been doing in the many months since starting the quiet period. I suspect that we may be further along the path to approval than many have thought.
Gary
